Subject:
- Active Substance: Ramucirumab
- Name: Cyramza®
- Therapeutic area: Gastric or gastro-oesophageal junction adenocarcinoma
- Pharmaceutical company: Lilly Deutschland GmbH
Time table:
- Publication of final assessment: 20.03.2015
Assessment information:
- Title: Ramucirumab in combination with Paclitaxel as second-line treatment for adult patients with advanced gastric or gastro-oesophageal junction adenocarcinoma
- Author/Co-Author: NIPHNO (Norway), AAZ (Croatia)
- Dedicated Reviewers: MoH Slovak Republic (Slovakia), FIMEA (Finland), GYMSZI (Hungary), UCSC Gemelli (Italy), HAS (France)
› G-BA assessment available (D-224)